These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 37431594)

  • 1. Sample size determination for adaptive crossover trial in detecting gene-drug interactions.
    Chen HY; Darbar D
    Stat Methods Med Res; 2023 Sep; 32(9):1680-1693. PubMed ID: 37431594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sample size determination for testing nonequality under a three-treatment two-period incomplete block crossover trial.
    Lui KJ; Chang KC
    Biom J; 2015 May; 57(3):410-21. PubMed ID: 25757940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of trial design on the estimation of drug potency and power in clinical trials of haemophilia with inhibitors.
    Larsen MS; Juul RV; Kreilgaard M; Kristensen AT; Simonsson USH
    Eur J Pharm Sci; 2018 Oct; 123():531-538. PubMed ID: 30077714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Controlling type 1 error rate for sequential, bioequivalence studies with crossover designs.
    Rasmussen HE; Ma R; Wang JJ
    Pharm Stat; 2019 Jan; 18(1):96-105. PubMed ID: 30370634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A flexible sample size solution for longitudinal and crossover cluster randomized trials with continuous outcomes.
    Wang J; Cao J; Zhang S; Ahn C
    Contemp Clin Trials; 2021 Oct; 109():106543. PubMed ID: 34450326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tests for inter-subject and total variabilities under crossover designs.
    Lee Y; Shao J; Chow SC; Wang H
    J Biopharm Stat; 2002 Nov; 12(4):503-34. PubMed ID: 12477072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blinded and unblinded sample size reestimation in crossover trials balanced for period.
    Grayling MJ; Mander AP; Wason JMS
    Biom J; 2018 Sep; 60(5):917-933. PubMed ID: 30073679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alternative models and randomization techniques for Bayesian response-adaptive randomization with binary outcomes.
    Proper J; Connett J; Murray T
    Clin Trials; 2021 Aug; 18(4):417-426. PubMed ID: 33926267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cluster randomised crossover trials with binary data and unbalanced cluster sizes: application to studies of near-universal interventions in intensive care.
    Forbes AB; Akram M; Pilcher D; Cooper J; Bellomo R
    Clin Trials; 2015 Feb; 12(1):34-44. PubMed ID: 25475880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Bayesian sequential design with adaptive randomization for 2-sided hypothesis test.
    Yu Q; Zhu L; Zhu H
    Pharm Stat; 2017 Nov; 16(6):451-465. PubMed ID: 28980435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Practical approaches for design and analysis of clinical trials of infertility treatments: crossover designs and the Mantel-Haenszel method are recommended.
    Takada M; Sozu T; Sato T
    Pharm Stat; 2015; 14(3):198-204. PubMed ID: 25776032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Power and sample size for GEE analysis of incomplete paired outcomes in 2 × 2 crossover trials.
    Tang Y
    Pharm Stat; 2021 Jul; 20(4):820-839. PubMed ID: 33738918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Power estimation using a population pharmacokinetics model with optimal design by clinical trial simulations: application in pharmacokinetic drug-drug interaction studies.
    Yang S; Beerahee M
    Eur J Clin Pharmacol; 2011 Mar; 67(3):225-33. PubMed ID: 21125264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sample size calculation for the Power Model for dose proportionality studies.
    Sethuraman VS; Leonov S; Squassante L; Mitchell TR; Hale MD
    Pharm Stat; 2007; 6(1):35-41. PubMed ID: 17323313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An evaluation of inferential procedures for adaptive clinical trial designs with pre-specified rules for modifying the sample size.
    Levin GP; Emerson SC; Emerson SS
    Biometrics; 2014 Sep; 70(3):556-67. PubMed ID: 24766094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sample size determination for alternate periods of use study designs with binary responses.
    Morel JG; Neerchal NK
    J Biopharm Stat; 2012; 22(2):351-67. PubMed ID: 22251179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Controlling the type I error rate in two-stage sequential adaptive designs when testing for average bioequivalence.
    Maurer W; Jones B; Chen Y
    Stat Med; 2018 May; 37(10):1587-1607. PubMed ID: 29462835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exact sample-size determination in testing non-inferiority under a simple crossover trial.
    Lui KJ; Chang KC
    Pharm Stat; 2012; 11(2):129-34. PubMed ID: 22232060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adaptive clinical trial designs with pre-specified rules for modifying the sample size: understanding efficient types of adaptation.
    Levin GP; Emerson SC; Emerson SS
    Stat Med; 2013 Apr; 32(8):1259-75; discussion 1280-2. PubMed ID: 23081665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.